1. Clinical Overview of LL-37

Molecule: LL-37 — 37–amino-acid C-terminal fragment of human cathelicidin antimicrobial protein (hCAP-18) · Classification: Host-defense peptide (HDP) with antimicrobial, antiviral, antifungal, antibiofilm, immunomodulatory, wound-healing, and angiogenic properties.

Physiologic Significance: LL-37 is produced by neutrophils, macrophages, keratinocytes, epithelial surfaces, and bone marrow progenitors. Essential for first-line immune defense, pathogen clearance, mucosal barrier protection, tissue repair, and immune system balancing.

Low LL-37 levels are associated with: Chronic infection, poor wound healing, biofilm-forming infections, immune dysfunction, chronic sinusitis, and inflammatory skin conditions.

2. Mechanisms of Action

2.1 Direct Antimicrobial Effects

Effective against Gram-positive bacteria, Gram-negative bacteria, MRSA, Pseudomonas, mycobacteria, fungi, parasites, and multiple viruses (enveloped and non-enveloped).

Actions: Membrane destabilization · Disruption of biofilm structures · Inhibition of bacterial adhesion · Viral envelope destabilization

2.2 Immunomodulatory

Balances innate and adaptive immunity, enhances macrophage activity, regulates cytokines (IL-6, TNF-α, IL-10), reduces chronic inflammatory cascades, increases chemotaxis for controlled immune response.

Clinical benefit: Powerful non-immunosuppressive anti-infective immunomodulator.

2.3 Mucosal & Epithelial Repair

Accelerates healing in skin, GI tract, nasal/sinus mucosa, respiratory surfaces, and urogenital tissues via angiogenesis enhancement, collagen deposition, re-epithelialization, and wound contraction regulation.

2.4 Anti-Biofilm Activity

Biofilms cause chronic, recurrent infections. LL-37 disrupts biofilm formation, EPS matrices, and bacterial quorum sensing — crucial for chronic sinusitis, chronic UTI, Lyme co-infections, Candida biofilms, and infected wounds.

3. Evidence Summary — Clinical Domains

3.1 Chronic & Recurrent Infections

Chronic sinusitis, chronic bronchitis, chronic UTIs, Lyme-related infections, biofilm-associated infections, non-healing wounds, skin infections.

3.2 Wound Healing & Regenerative Medicine

Surgical incisions, burns, ulcers, diabetic wounds, pressure injuries — via increased angiogenesis, improved collagen remodeling, reduction in microbial load.

3.3 Dermatology & Aesthetic Medicine

Acne (antimicrobial + anti-inflammatory), post-procedure healing, rosacea (modulates innate immunity), psoriasis and eczema (adjunct), chronic dermatitis.

3.4 Immune System Optimization

Normalizes innate immune dysfunction, chronic inflammation, poor pathogen clearance. Particularly useful for immunosenescence, chronic inflammatory conditions, frequent infections.

3.5 Respiratory & Sinus Applications

Chronic rhinosinusitis, allergic fungal sinusitis, recurrent bronchitis, post-viral recovery, chronic cough (inflammatory phenotype).

4. Administration Routes & Protocols

4.1 Subcutaneous (Most Common)

Standard Anti-Infective: 100–300 mcg SC, 3× weekly
Moderate Infection: 300–500 mcg SC, 3× weekly
Aggressive Anti-Biofilm: 500–800 mcg SC, 3–5× weekly (4–6 week course)
Cycle: 4–12 weeks · Maintenance: 1–2× weekly as needed

4.2 Intramuscular (IM)

Dose: 300–1,000 mcg IM, 1–2× weekly · Higher systemic exposure for chronic/recurrent infections

4.3 Topical

Dermatology/Aesthetic: 0.1–0.5% gel/cream/serum, 1–2× daily
Wound Care: 0.5–1% hydrogel dressing, 1–2× daily
Applications: Non-healing wounds, acne, post-microneedling, chronic dermatitis, cellulitis adjunct

4.4 Intranasal (Chronic Sinusitis)

Dose: 50–100 mcg per nostril, 1–2× daily · Duration: 2–4 weeks · Must be clinically supervised

4.5 Nebulized (Advanced/Specialty Only)

Dose: 50–100 mcg in saline, nebulized 1× daily · Use with extreme caution due to airway sensitivity · For chronic, refractory respiratory infections only

5. Clinical Decision Trees

Decision Tree 1 — Is LL-37 Indicated?

Chronic or recurrent infection present? → YES → LL-37 appropriate

Biofilm-associated or antibiotic-resistant? → Strong LL-37 indication

Non-healing wound or ulcer? → LL-37 + wound-care protocol

Skin inflammation or acne? → Topical LL-37 ± SC

Chronic sinusitis or respiratory inflammation? → Intranasal LL-37

Autoimmune disease? → Case-by-case evaluation

Decision Tree 2 — Dosing Strategy

Mild infection / immune dysfunction? → 100–300 mcg SC 3× weekly

Moderate chronic infections? → 300–500 mcg SC 3× weekly

Severe / biofilm? → 500–800 mcg SC 3–5× weekly

Dermatologic? → Topical LL-37 0.1–0.5%

Chronic sinusitis? → Intranasal 50–100 mcg each nostril

6. Integrated Treatment Archetypes

Archetype A — Chronic Sinusitis & Biofilm

Systemic: LL-37 300–500 mcg SC 3× weekly + KPV 250–500 mg/day + Glutathione IV 1–2× weekly

Local: Intranasal LL-37 BID + saline/budesonide rinses

Archetype B — Chronic Wound / Ulcer

Local: LL-37 0.5–1% gel BID + GHK-Cu serum + TB-500 SC near wound margins

Systemic: LL-37 SC 300–500 mcg + Glutathione for detox & redox

Archetype C — Dermatology & Aesthetic Post-Procedure

Topical: LL-37 0.1–0.3% post-needling or RF + GHK-Cu nightly

Systemic: KPV oral for inflammation control

Archetype D — Immune Optimization

Systemic: LL-37 100–300 mcg SC + NAD+ weekly + KPV oral + Glutathione IM/IV

7. Expected Clinical Timeline

Day 1–5: Reduced inflammation; improved sinus/skin symptoms
Week 1–2: Pathogen load reduction; wound improvement
Week 2–4: Significant improvement in chronic infections
Week 4–12: Enhanced immune resilience and reduced recurrence

8. Contraindications & Adverse Effects

Absolute Contraindications

Known hypersensitivity
Pregnancy/lactation (insufficient data)

Relative Contraindications

Autoimmune disease (immune stimulation potential)
Severe asthma (nebulized caution)
Severe inflammatory flare states

Adverse Effects

Injection-site pain, Herxheimer-like reaction (detox flare), temporary fatigue, mild fever/chills (immune activation), nasal burning (intranasal). Most side effects are mild and transient.

9. Monitoring

Infection symptoms
Wound healing progression
Sinus/respiratory function
Inflammatory markers (CRP, ESR)
Liver function (if long-term therapy)

Legal Disclaimer

This document is provided solely for educational and informational purposes. LL-37 (Human Cathelicidin Antimicrobial Peptide) and other peptides referenced herein are not FDA-approved drugs. Their clinical use may constitute off-label or investigational use. Peptide Protocol Portal makes no representations or warranties. Clinical decisions remain the sole responsibility of the licensed practitioner. By using this document, the reader agrees that Peptide Protocol Portal shall not be held liable for any damages or adverse outcomes. Use at your own risk.

References — LL-37 Clinical Reference Guide

Foundational Discovery & Mechanistic Biology

1. Larrick, J. W., et al. Human CAP18: A member of the cathelicidin family. Infection and Immunity, 63(4), 1291–1297 (1995).

2. Zhang, Z., et al. Structure–function analysis of LL-37. Biochemistry, 40(17), 6455–6463 (2001).

3. Sørensen, O. E., et al. Human cathelicidin antimicrobial peptide expression and function. J Biol Chem, 276(7), 5355–5362 (2001).

4. Dürr, U. H., et al. LL-37: A multifunctional antimicrobial peptide. Biochim Biophys Acta, 1758(9), 1408–1425 (2006).

Antimicrobial, Antiviral & Antifungal

5. Bals, R., et al. Antibacterial peptides in airway epithelium. Am J Respir Cell Mol Biol, 23(6), 652–658 (2000).

6. Tripathi, S., et al. LL-37 inhibits influenza virus replication. J Immunol, 190(1), 419–426 (2013).

7. Wong, J. P., et al. Antiviral activity of LL-37 against respiratory viruses. J Virol, 85(18), 9388–9396 (2011).

8. Håkansson, J., et al. LL-37 disrupts Candida albicans biofilms. Antimicrob Agents Chemother, 55(1), 293–300 (2011).

Biofilm Disruption

9. Overhage, J., et al. LL-37 prevents biofilm formation by Pseudomonas aeruginosa. Infect Immun, 76(9), 4176–4182 (2008).

10. Wang, G. LL-37 fragments as anti-biofilm agents. Biochim Biophys Acta, 1838(9), 2202–2211 (2014).

Wound Healing & Angiogenesis

11. Heilborn, J. D., et al. LL-37 is essential for normal human wound healing. J Invest Dermatol, 122(5), 1120–1127 (2004).

12. Koczulla, R., et al. LL-37 induces angiogenesis. J Clin Invest, 111(11), 1665–1672 (2003).

Dermatology & Immune Modulation

13. Yamasaki, K., et al. Dysregulated LL-37 expression in rosacea. Nature Medicine, 13(8), 975–983 (2007).

14. Kahlenberg, J. M., & Kaplan, M. J. LL-37 in immune activation and inflammation. Curr Opin Rheumatol, 25(4), 440–447 (2013).

LL-37 (Human Cathelicidin)